Neurocognitive Function in Brain Tumors
- 632 Downloads
Cognitive dysfunction associated with both the disease and the adverse effects of radiotherapy (RT) and chemotherapy is a significant problem among brain tumor patients. Currently, it is considered the most frequent complication among long-term survivors. A review of the literature indicates that whole-brain RT alone or in combination with chemotherapy results in cognitive dysfunction more pronounced than from either partial RT or chemotherapy alone. The cognitive domains sensitive to treatment adverse effects include attention, executive functions, memory, and graphomotor speed. An increasing number of studies and clinical trials have incorporated cognitive outcome measures and have provided relevant information about therapy-related neurotoxicity and the incidence of cognitive dysfunction. Recent studies have begun to elucidate the pathophysiologic mechanisms that may underlie RT and chemotherapy injury to the brain. Although there are no established preventive or therapeutic interventions for treatment-induced cognitive dysfunction, this is an area of growing interest, and several approaches are currently under investigation.
KeywordsCognitive Treatment delayed effects Neurotoxicity
Dr. Correa is a co-investigator in an ongoing brain tumor study supported by Genentech (no salary support is provided). She also has been a consultant to Genentech regarding cognitive outcome studies involving brain cancer patients.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Behin A, Delattre, J-Y: Neurologic sequelae of radiotherapy on the nervous system. In Cancer Neurology in Clinical Practice. Edited by Schiff D, Wen PY. Totowa, NJ: Humana Press Inc.; 2003:173–191.Google Scholar
- 6.•• Dietrich J, Han R, Yang Y, et al.: CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and vivo. J Biol 2006, 5:1–23. This is an excellent paper describing in vitro and in vivo (mice) studies demonstrating that common chemotherapy agents caused increased cell death and decreased cell division in the subventricular zone and in the dentate gyrus of the hippocampus (regions involved in neurogenesis). These effects were seen in doses that were not effective in causing cell death in tumor cell lines. CrossRefGoogle Scholar
- 7.•• Gehring K, Sitskoorn MM, Aaronson NK, et al.: Interventions for cognitive deficits in adults with brain tumours. Lancet Neurol 2008, 7:548–560. This article provides a comprehensive review of empiric studies using pharmacologic interventions to treat and prevent cognitive impairment in brain tumor patients; studies using cognitive rehabilitation techniques also are reviewed. CrossRefPubMedGoogle Scholar
- 9.• Meyers CA, Brown PD: Role and relevance of neurocognitive assessments in clinical trials of patients with CNS tumors. J Clin Oncol 2006, 24:1305–1309. This study outlines the rationale for performing prospective neuropsychological evaluations at diagnosis and following treatment in patients with brain tumors. A brief test battery including standardized cognitive tests and quality-of-life questionnaires is suggested for use in neuro-oncology trials. CrossRefPubMedGoogle Scholar
- 10.• Correa DD, Maron L, Harder H, et al.: Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007, 18:1145–1151. This article provides a comprehensive review of cognitive studies in PCNSL patients. It also proposes the use of a standardized cognitive test battery in future collaborative studies. CrossRefPubMedGoogle Scholar
- 11.National Cancer Institute, National Institute of Neurological Disorders and Stroke: Report of the Brain Tumor Progress Review Group, November 2000. Available at http://osp.nci.nih.gov/Prg_assess/PRG/BTPGR.
- 19.• van Breemen MSM, Wilms EB, Vecht CJ: Epilepsy in patients with brain tumors: epidemiology, mechanisms, and management. Lancet Neurol 2007, 6:421–430. This article discusses the role of antiepileptic drugs in the management of seizures in brain tumor patients. Prophylactic use was not suggested, and interactions with chemotherapeutic agents and cognitive side effects are among the issues to consider in decision making. CrossRefPubMedGoogle Scholar
- 20.• Bosma I, Vos MJ, Heimans JJ, et al.: The course of neurocognitive functioning in high grade glioma patients. Neuro Oncol 2007, 9:53–62. This study describes the results of longitudinal cognitive follow-up before and after treatment with RT in high-grade gliomas. Tumor progression and antiepileptic agents were associated with neurocognitive decline. CrossRefPubMedGoogle Scholar
- 21.DeAngelis LM, Posner JB: Side effects of radiation therapy. In Neurologic Complications of Cancer, edn 2. Edited by DeAngelis LM, Posner JB. New York: Oxford University Press; 2009:551–555.Google Scholar
- 31.•• Dietrich J, Monje M, Wefel J, et al.: Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008, 13:1285–1295. The authors provide a review of cognitive, imaging, and biological changes associated with chemotherapy and RT in cancer patients. CrossRefPubMedGoogle Scholar
- 32.• Winocur G, Vardy J, Binns MA, et al.: The effects of anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006, 85:66–75. These investigators reported deficits in several tasks associated with learning and memory in mice administered methotrexate and 5-fluorouracil. CrossRefPubMedGoogle Scholar
- 39.• Keime-Guibert F, Chinot O, Tailandier L, et al.: Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007, 356:1527–1535. This article reports the findings of a randomized trial comparing focal RT with supportive care in elderly patients (70 years or older) with high-grade tumors. RT was associated with a modest improvement in survival without significant neurocognitive decline at a median follow-up of 21 weeks. CrossRefPubMedGoogle Scholar
- 41.• Platta CS, Khuntia D, Mehta MP, Suh JH: Current treatment strategies for brain metastasis and complications from therapeutic techniques. Am J Clin Oncol (doi: 10.1097/COC.0b013e318194f744). This article provides an overview of the most widely used therapies for brain metastases and discusses strategies to maintain or improve cognitive functions in these patients.
- 42.Chang EL, Wefel JS, Maor MH, et al.: A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007, 60:285–292.Google Scholar
- 44.Metha MP, Shapiro WR, Phan SC, et al.: Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009, 73:1069–1076.Google Scholar
- 45.• Brown PD, Asher AL, Farace E: Adjuvant whole brain radiotherapy: strong emotions decide but rational studies are needed. Int J Radiat Oncol Biol Phys 2008, 70:1305–1309. This article discusses recent studies involving patients with brain metastases treated with whole-brain RT with regard to treatment efficacy and neurocognitive side effects. It emphasizes the importance of including serial neurocognitive assessment in large clinical trials to further elucidate the risks and benefits of ongoing and newly developed therapies. PubMedGoogle Scholar
- 47.Laack NN, Brown PD, Furth A, et al.: Neurocognitive function after radiotherapy (RT) for supratentorial low-grade gliomas (LGG): results of a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 2003, 57:S134.Google Scholar
- 49.•• Douw L, Klein M, Fagel SA, et al.: Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009, 8:810–818. This study reports the findings of longitudinal cognitive follow-up for 65 low-grade glioma patients who participated in a prior study. The authors reported a decline in cognitive functions, particularly in attention, in patients treated with RT. CrossRefPubMedGoogle Scholar
- 52.Correa DD, DeAngelis LM, Shi W, et al.: Cognitive functions and APOE genotype in low grade glioma patients. Neuro Oncol 2007, 81:175–184.Google Scholar
- 54.Abrey LE: Primary central nervous system lymphoma. Curr Opin Neurol 2009 Sep 5 (Epub ahead of print).Google Scholar
- 55.• Ghia A, Tome WA, Thomas S, et al.: Distribution of brain metastases in relation to the hippocampus: implications for neurocognitive functional preservation. Int J Radiat Oncol 2007, 68: 971–977. This study explored the viability of developing a tomotherapy plan to deliver hippocampus-sparing whole brain radiation to patients with brain metastasis; this method could potentially reduce the neurocognitive deficits associated with RT. CrossRefGoogle Scholar